How Does AI Turn Wearable Data into Evidence for Pharma?

AI turns wearable data into evidence pharma teams can use by cleaning, standardizing and interpreting signals from smartwatches, rings, patches and biosensors. Raw wearable data is noisy and fragmented across manufacturers, so it is not useful for regulatory decision-making on its own. Once AI filters artifacts, aligns metrics across devices and documents every transformation, the data can support clinical trials, post-market surveillance and digital biomarker development.

Real-world data is becoming as valuable to the pharmaceutical industry as traditional clinical trial data, and wearable devices are among the fastest-growing sources of that real-world evidence. For pharma teams to rely on wearable signals, the data must reach a level of accuracy, consistency and reliability that aligns with regulatory expectations.

AI turns raw wearable data into structured insights by resolving the fragmentation between devices: each manufacturer uses different sensors, algorithms, measurement methods and formats.

AI addresses this fragmentation by:

Without this normalization step, pharma teams cannot compare biometric signals across subjects or devices, which is a requirement for reducing trial variability and meeting regulatory standards.

AI improves the accuracy of wearable data by correcting for the noise and real-world variability that wearable sensors are susceptible to.

AI algorithms improve data quality through:

These steps make wearable datasets more consistent, moving them closer to what FDA and EMA submissions require.

AI enables digital biomarkers, which are quantifiable physiological and behavioral signals derived from continuous sensor data, by finding patterns in that data that humans or traditional tools would miss.

Digital biomarkers can measure:

Digital biomarkers open new endpoints for clinical research and help pharma companies:

AI supports regulatory compliance by making wearable data processing traceable and consistent. Regulators expect digital tools used in trials to meet clear requirements; the FDA, for example, publishes guidance on digital health technologies for remote data acquisition in clinical investigations. Those requirements cover:

AI systems can help meet these standards by:

With the right AI infrastructure in place, wearable data can meet the quality thresholds required for regulatory submission packages.

AI accelerates real-world evidence generation by making wearable data usable beyond clinical trials, in post-market surveillance and longitudinal patient monitoring.

AI helps pharma teams:

This moves pharma from episodic data collection to continuous evidence generation, which regulators increasingly encourage.

AI-ready wearable data pipelines give pharma companies an advantage in drug development by:

Over the next decade, wearable-derived evidence will likely enter more rigorous regulatory pathways, supported by AI systems that keep the data high-quality and trustworthy. For the trial side of this shift, see how wearables are used in clinical trials and digital health.

Wearable devices provide continuous, real-world insight into human health, but AI is what raises that information to evidence pharma teams can trust. From data cleaning and standardization to digital biomarker development and regulatory compliance, AI transforms messy, fragmented sensor data into meaningful signals for clinical and scientific work. As the industry moves toward decentralized trials, digital endpoints and preventive care, AI-powered wearable data will become indispensable to drug development.

The data layer comes first: ROOK Connect collects and normalizes wearable data from 72 data sources and more than 500 devices into one schema that AI pipelines can consume. ROOK moves and standardizes the data; it does not diagnose or replace clinical judgment. For the modeling steps, read how to use wearable data in AI health models, or explore the data schema in the ROOK developer documentation.